|
1) Nishikawa T, Omura M. Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Roai Hospital. Biomed Phamacother. 2000; 54 Suppl 1: 83-5
|
|
|
|
|
2) Omura M, et al. Prospective syudy on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004; 27: 193-202
|
|
|
|
|
3) Pitt B, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341: 709-17
|
|
|
|
|
|
4) Gomez-Sanchez, et al. Aldosterone biosynthesis in the rat brain. Endocrinology. 1997; 138: 3369-73
|
|
|
|
|
|
5) Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in the failing ventricles in humans. Circulation. 2001; 103: 72-7
|
|
|
|
|
|
6) Hatakeyama H, Miyamori I, Fujita T, et al. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem. 1994; 269: 24316-20
|
|
|
|
|
|
7) Nishikawa T, Suematsu S, Saito J, et al. Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL). J Steroid Biochem Molec Biol. 2005; 96: 309-16
|
|
|
|
|
|
8) Struthers AD. Impact of aldosterone on vascular pathophysiology. Congest Heart Fail. 2002; 8: 18-22
|
|
|
|
|
|
9) Guido Lasta-Gonzalez, et al. The role of aldo-sterone in cardiovascular disease in people with diabetes and hypertension: an update. Curr Diab Rep. 2008; 8: 203-7
|
|
|
|
|
|
10) Wada T, Ohshima S, Fujisawa E, et al. Aldo-sterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS)1 and IRS2 via a reactive oxygen species-mediated pathway in 3t3-L1 adipocytes. Endocrinology. 2009; 150: 1662-9
|
|
|
|
|
|
11) 松澤陽子, 正路由紀, 吉村公一郎, 他. 血液中および唾液中コルチゾール, コルチゾン測定の臨床的意義に関する検討—肥満を伴う2型糖尿病男性患者の分析から—. J Metabolic Syndrome. 2007; 4: 18-23
|
|
|
|
|
|
12) Gian R, et al. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab. 2008; 93: 2566-71
|
|
|
|
|
|
13) Krug AW, Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor？ Hypertension. 2008; 51: 1252-8
|
|
|
|
|
|
14) Ehrhart-Bornstein M, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A. 2003; 100: 14211-6
|
|
|
|
|
|
15) Case detection, diagnosis, and treatment of pa-tients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008; 93: 3266-81
|
|
|
|
|
|
16) Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Characterization of resistant hypertension. - Association between resistant hypertension, aldo-sterone, and persistent intravascular expansion. Arch Intern Med. 2008; 168: 1159-64
|
|
|
|
|
|
17) Matrozova J, Steichen O, Amar L, et al. Fasting plasma glucose and serum lipids in patients with parimary aldosteronism- A controlled cross-sectional study. Hypertension 2009; 53: 605-10
|
|
|
|
|
|
18) Pimenta E, Calhoun DA. Aldosterone and metabolic dysfunction-An unresolved issue. Hypertension. 2009; 53: 585-6
|
|
|
|
|
|
19) Mosso LM, Carvajal CA, Maiz A, et al. A possible association between primary aldosteronism and a lower β-cell function. J Hypertens. 2007; 25: 2125-2130
|
|
|
|
|
|
20) Fallo F, Veglio F, Bartello C, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006; 91: 454-9
|
|
|
|
|
|
21) Giacchetti G, Ronconi V, Turchi F, et al. Aldo-sterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens. 2007; 25: 177-86
|
|
|
|
|
|
22) 武田仁勇, 他. 副腎ホルモン産生異常に関する調査研究 平成19年度 総括・分担研究報告書 原発性アルドステロン症における糖代謝異常. p. 149-51
|
|
|
|
|
|
23) 西川哲男, 他. 副腎ホルモン産生異常に関する調査研究 平成19年度 総括・分担研究報告書. 原発性アルドステロン症全国アンケート調査集計第一報. p. 20-1
|
|
|
|
|
|
24) Milliez P, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005; 45: 1243-8
|
|
|
|
|
|
25) Shibata S, Nagase M, Yoshida S, et al. Modifi-cation of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008; 14: 1370-6
|
|
|
|
|
|
26) Leone A, et al. Treatment of hypertension with valsartan combined with spironolactone. Intern Urol Nephrol. 2000; 32: 161-3
|
|
|
|
|
|
27) Krum H, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension. 2002; 40: 117-23
|
|
|
|
|
|
28) Saruta T, et al. Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study. J Clin Hypertens. 2004; 6: 175-83
|
|
|
|
|
|
29) Flack JM, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol. 2003; 41: 1148-55
|
|
|
|
|
|
30) White WB, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension. 2003; 41: 1021-6
|
|
|
|
|
|
31) Pitt B, Remme WJ, Zannad F. Eplerenone post primary results of the EPHESUS trial. N Engl J Med. 2003; 384: 1309-21
|
|
|
|
|
|
32) Iraqui W, Rossignol P, Angioi M, et al. Extra-cellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure-insight from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS) study. Circulation. 2009; 119: 2471-9
|
|
|
|
|
|
33) Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med. 2001; 345: 925-6
|
|
|
|
|
|
34) Catena C, Colussi G, Nadalini E, et al. Cardio-vascular outocomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008; 168: 80-5
|
|
|
|
|
|
35) Sechi LA, Novello M, Lapenna R, et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA. 2006; 295: 2638-45
|
|
|
|
|
|
36) Karagiannis A, Tziomalos K, Papageorgiou A, et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother. 2008; 9: 509-15
|
|
|
|
|